Genomic Health Inc (GHDX)

30.95
0.19 0.62
NASDAQ : Health Care
Prev Close 30.76
Open 30.82
Day Low/High 30.62 / 31.22
52 Wk Low/High 20.05 / 35.79
Volume 85.30K
Avg Volume 134.00K
Exchange NASDAQ
Shares Outstanding 34.07M
Market Cap 1.09B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Four New Studies Of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value Of Test In Guiding Early-stage Prostate Cancer Risk Assessment And Treatment Selection

Four New Studies Of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value Of Test In Guiding Early-stage Prostate Cancer Risk Assessment And Treatment Selection

Presentations at 2017 ASCO Genitourinary Cancers Symposium in Orlando, Feb. 16-18, Underscore Test's Clinical Utility in Low- and Intermediate-risk Patients

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Announces Inclusion Of Oncotype DX® In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging

Genomic Health Announces Inclusion Of Oncotype DX® In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging

For the First Time, AJCC Adds Molecular Markers to Staging Criteria, Including Oncotype DX along with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 Status

Genomic Health Announces Results From Multiple Oncotype DX® Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World

Genomic Health Announces Results From Multiple Oncotype DX® Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World

Presentations at 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) Highlight Unique Value of Oncotype DX in Tailoring Treatment Across the Breast Cancer Patient Journey

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Data Presented for First Time at ESMO 2016 Congress Highlight Company's Commitment to Delivering Rigorous, Clinically Actionable Liquid-based Tests for Late-stage Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Two Large International Studies Underscore Ability of Oncotype DX to Identify Patients with Node-positive Breast Cancer Who Can Forego Chemotherapy and Its Side Effects

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Validation Study Led by Memorial Sloan Kettering Cancer Center, Published in JAMA Oncology, Demonstrated Patients with AR-V7 Positive Circulating Tumor Cells Have Significantly Better Outcomes if Treated with Chemotherapy versus Hormonal Treatments

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women